Search

Displaying results 3301 - 3310 of 10000 in total
  1. Drug

    Lisuride

    go.drugbank.com/drugs/DB00589
    Approved

    It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists). … An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists).

    Categories: Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Antagonists
  2. Drug

    NE-180

    go.drugbank.com/drugs/DB05619
    Experimental

    NE-180 was under investigation in a clinical trial conducted in the European Union.

  3. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    It was synthesized in the late 1970s and developed as a potential treatment for depression. … [A19824] Vanoxerine was later evaluated as a potential treatment for cocaine addiction due to its ability to block dopamine reuptake with a slower dissociation rate than cocaine.

    Synonyms: 1-(2-(bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Streptococcus pneumoniae type 4 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10322
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  5. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder.

    Products: Travase Ointment 82000 Casein Units/gm
  6. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis (MS … CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

  7. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    Frespaciguat is under investigation in clinical trial NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With … Frespaciguat has a monoisotopic molecular weight of 608.14 Da.

  8. Target

    Major prion protein

    go.drugbank.com/bio_entities/BE0001105
    TargetEnzymeHumans

    Its primary physiological function is unclear. May play a role in neuronal development and synaptic plasticity. May be required for neuronal myelin sheath maintenance. May promote myelin homeostasis through acting as an agonist for ADGRG...

    Synonyms: PRIP
  9. Drug

    Lefamulin

    go.drugbank.com/drugs/DB12825
    Approved

    [A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. … [L8093] This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. … Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received